A phase II multicenter study to assess the feasibility and efficacy of the addition of an interphase cycle with flotetuzumab prior to start conditioning for an allogeneic HCT in AML with detectable MRD after 2 cycles of intensive chemotherapy
20 Dec 2021: The pharmaceutical company MacroGenics no longer wants to support the HO162 study.